• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

面部移植8年后的面部创伤

Facial Trauma 8 years after a Face Transplantation.

作者信息

Goutard Marion, Lellouch Alexandre G, Dussol Bertrand, Lantieri Laurent A

机构信息

Department of Plastic Reconstructive Surgery, European Georges Pompidou Hospital (AP-HP), Paris, France.

Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

出版信息

Plast Reconstr Surg Glob Open. 2021 May 21;9(5):e3575. doi: 10.1097/GOX.0000000000003575. eCollection 2021 May.

DOI:10.1097/GOX.0000000000003575
PMID:34036023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8140768/
Abstract

Over the past 20 years, vascularized composite allografts (VCAs) have emerged as a realistic option in reconstructive surgery. Long-term follow-up reports indicate that face transplant patients have gained in quality of life and social integration. However, they require close monitoring of their immunosuppressive therapy because they are at high-risk for acute rejection episodes, leading eventually to chronic rejection and allograft loss. Reported acute rejection episodes in VCA recipients occur due to low immunosuppressive therapy (mainly due to lack of patient compliance or decreased doses of immunosuppressants to counter side-effects). Repeated mechanical traumas have recently been shown to trigger acute rejection episodes, especially in hand transplant patients. This article reports our experience of a 10-year follow-up of a 57-year-old face transplant patient and the management of his accidental facial trauma. To our knowledge, our patient is the first to undergo a major trauma on his VCA endangering his graft function and vitality. This report discusses the management of an acute surgical situation in those particular patients, and the challenges that arise to avoid acute rejection of the allograft. Ten years into his face transplant and at 18 months follow-up after his facial trauma, our patient shows great aesthetic and functional outcomes and remains rejection-free; a very encouraging result for all VCA candidates.

摘要

在过去20年里,血管化复合组织异体移植(VCA)已成为重建手术中的一种现实选择。长期随访报告表明,面部移植患者的生活质量和社会融入度有所提高。然而,由于他们面临急性排斥反应发作的高风险,最终可能导致慢性排斥反应和移植物丢失,因此需要密切监测其免疫抑制治疗情况。VCA受者报告的急性排斥反应发作是由于免疫抑制治疗不足(主要是由于患者依从性差或为应对副作用而减少免疫抑制剂剂量)。最近发现,反复的机械性创伤会引发急性排斥反应发作,尤其是在手部移植患者中。本文报告了我们对一名57岁面部移植患者进行10年随访以及对其意外面部创伤的处理经验。据我们所知,我们的患者是首例其VCA遭受严重创伤并危及移植物功能和活力的患者。本报告讨论了这类特殊患者急性外科情况的处理,以及为避免同种异体移植物急性排斥反应而出现的挑战。在面部移植10年后以及面部创伤后18个月的随访中,我们的患者显示出了极佳的美学和功能效果,且未发生排斥反应;这对所有VCA候选者来说都是一个非常令人鼓舞的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c46/8140768/1b4288f5c6c4/gox-9-e3575-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c46/8140768/2fba7c787823/gox-9-e3575-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c46/8140768/f808dd7efce6/gox-9-e3575-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c46/8140768/1b4288f5c6c4/gox-9-e3575-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c46/8140768/2fba7c787823/gox-9-e3575-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c46/8140768/f808dd7efce6/gox-9-e3575-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c46/8140768/1b4288f5c6c4/gox-9-e3575-g003.jpg

相似文献

1
Facial Trauma 8 years after a Face Transplantation.面部移植8年后的面部创伤
Plast Reconstr Surg Glob Open. 2021 May 21;9(5):e3575. doi: 10.1097/GOX.0000000000003575. eCollection 2021 May.
2
The Significance of Vascular Alterations in Acute and Chronic Rejection for Vascularized Composite Allotransplantation.血管改变在急性和慢性排斥反应中对血管化复合组织移植的意义。
J Vasc Res. 2019;56(4):163-180. doi: 10.1159/000500958. Epub 2019 Jul 2.
3
Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.血管化复合组织异体移植:预防急性排斥反应和慢性移植物退变的现行标准及新方法
Transpl Int. 2016 Jun;29(6):655-62. doi: 10.1111/tri.12652. Epub 2015 Sep 14.
4
Immunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes.面部和手部移植中的免疫抑制策略:对当前治疗方案和结果的全面系统综述
Front Transplant. 2024 Mar 6;3:1366243. doi: 10.3389/frtra.2024.1366243. eCollection 2024.
5
Infrared fluorescence imaging of lymphatic regeneration in nonhuman primate facial vascularized composite allografts.非人灵长类面部血管化复合组织同种异体移植中淋巴再生的红外荧光成像
Ann Plast Surg. 2012 Mar;68(3):314-9. doi: 10.1097/SAP.0b013e31824671e5.
6
Novel immunological and clinical insights in vascularized composite allotransplantation.血管化复合组织移植中的新免疫和临床见解。
Curr Opin Organ Transplant. 2019 Feb;24(1):42-48. doi: 10.1097/MOT.0000000000000592.
7
Long-Term Multifunctional Outcome and Risks of Face Vascularized Composite Allotransplantation.面部血管化复合组织异体移植的长期多功能结局与风险
J Craniofac Surg. 2015 Oct;26(7):2038-46. doi: 10.1097/SCS.0000000000002110.
8
Histopathology of chronic rejection in a nonhuman primate model of vascularized composite allotransplantation.血管化复合组织同种异体移植非人灵长类模型中慢性排斥反应的组织病理学。
Transplantation. 2013 May 27;95(10):1204-10. doi: 10.1097/TP.0b013e31828d1528.
9
Complex facial reconstruction by vascularized composite allotransplantation: the first Belgian case.通过血管化复合组织异体移植进行复杂面部重建:比利时首例病例。
J Plast Reconstr Aesthet Surg. 2015 Mar;68(3):362-71. doi: 10.1016/j.bjps.2014.11.005. Epub 2014 Nov 20.
10
Standardizing skin biopsy sampling to assess rejection in vascularized composite allotransplantation.标准化皮肤活检采样以评估血管化复合组织移植中的排斥反应。
Clin Transplant. 2013 Mar-Apr;27(2):E81-90. doi: 10.1111/ctr.12086. Epub 2013 Mar 3.

引用本文的文献

1
Perfusion of Limb Vascularized Composite Allotransplants: A Systematic Review of Published Protocols.肢体血管化复合组织异体移植的灌注:已发表方案的系统评价
Transpl Int. 2025 May 19;38:14132. doi: 10.3389/ti.2025.14132. eCollection 2025.
2
Mimicking Clinical Rejection Patterns in a Rat Osteomyocutaneous Flap Model of Vascularized Composite Allotransplantation.模拟血管化复合组织同种异体移植大鼠肌皮瓣模型中的临床排斥模式。
J Surg Res. 2024 Mar;295:28-40. doi: 10.1016/j.jss.2023.08.057. Epub 2023 Nov 16.
3
Effect of Immunosuppression on the Hybrid Skeleton of Vascularized Composite Allotransplants?

本文引用的文献

1
Mechanical Trauma and the Skin Immune System in Hand Transplant Rejection.手部移植排斥反应中的机械性创伤与皮肤免疫系统
Ann Surg. 2020 May;271(5):e115. doi: 10.1097/SLA.0000000000003817.
2
A Second Chance at Life.生命的第二次机会。
Camb Q Healthc Ethics. 2019 Jul;28(3):463-467. doi: 10.1017/S0963180119000380.
3
Trauma-induced Rejection in Vascularized Composite Allotransplantation.血管化复合组织移植中的创伤性排斥反应。
免疫抑制对血管化复合异体移植杂交骨骼的影响?
Plast Reconstr Surg Glob Open. 2022 Mar 24;10(3):e4226. doi: 10.1097/GOX.0000000000004226. eCollection 2022 Mar.
Ann Surg. 2020 May;271(5):e113-e114. doi: 10.1097/SLA.0000000000003365.
4
Graft vasculopathy of vascularized composite allografts in humans: a literature review and retrospective study.移植物血管病在人类带血管复合异体移植物中的表现:文献综述和回顾性研究。
Transpl Int. 2019 Aug;32(8):831-838. doi: 10.1111/tri.13421. Epub 2019 Apr 2.
5
Mechanisms of rejection in vascular composite allotransplantation.血管化复合组织异体移植中的排斥反应机制。
Curr Opin Organ Transplant. 2018 Feb;23(1):28-33. doi: 10.1097/MOT.0000000000000490.
6
Osteoporosis following heart transplantation and immunosuppressive therapy.心脏移植和免疫抑制治疗后的骨质疏松症。
Transplant Rev (Orlando). 2017 Oct;31(4):232-239. doi: 10.1016/j.trre.2017.08.002. Epub 2017 Aug 12.
7
Face transplant: long-term follow-up and results of a prospective open study.面部移植:一项前瞻性开放性研究的长期随访和结果。
Lancet. 2016 Oct 1;388(10052):1398-1407. doi: 10.1016/S0140-6736(16)31138-2. Epub 2016 Aug 25.
8
Principles of face transplant revision: beyond primary repair.面部移植修复原则:超越初次修复
Plast Reconstr Surg. 2014 Dec;134(6):1295-1304. doi: 10.1097/PRS.0000000000000760.
9
Feasibility, reproducibility, risks and benefits of face transplantation: a prospective study of outcomes.面部移植的可行性、可重复性、风险和获益:结局的前瞻性研究。
Am J Transplant. 2011 Feb;11(2):367-78. doi: 10.1111/j.1600-6143.2010.03406.x.
10
First human face allograft: early report.首例人类面部同种异体移植:早期报告。
Lancet. 2006 Jul 15;368(9531):203-9. doi: 10.1016/S0140-6736(06)68935-6.